Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang in aandelen
#3419
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aandeelprijs
$4.48
Marktkapitalisatie
$4.99B
Verandering (1 dag)
-5.20%
Verandering (1 jaar)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categorie
Healthcare
Omzet van Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Omzet in Jun 2026 TTM: $703.92M
Volgens de laatste financiële rapporten van Shenzhen Salubris Pharmaceuticals Co., Ltd. bedraagt de huidige omzet van het bedrijf (TTM) $703.92M. In 2024 behaalde het bedrijf een omzet van $549.69M een stijging ten opzichte van de omzet in het jaar 2023, die $475.42M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Shenzhen Salubris Pharmaceuticals Co., Ltd. van 2006 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $703.92M | 14.35% |
| 2025 | $615.57M | 11.98% |
| 2024 | $549.69M | 15.62% |
| 2023 | $475.42M | -5.82% |
| 2022 | $504.79M | 4.91% |
| 2021 | $481.19M | 14.79% |
| 2020 | $419.21M | -34.70% |
| 2019 | $642.00M | -5.07% |
| 2018 | $676.28M | 5.93% |
| 2017 | $638.43M | 15.63% |
| 2016 | $552.15M | 3.10% |
| 2015 | $535.54M | 15.07% |
| 2014 | $465.40M | 21.29% |
| 2013 | $383.71M | 30.83% |
| 2012 | $293.29M | 25.36% |
| 2011 | $233.95M | 18.99% |
| 2010 | $196.62M | 58.00% |
| 2009 | $124.44M | 61.08% |
| 2008 | $77.26M | 61.43% |
| 2007 | $47.86M | 83.90% |
| 2006 | $26.02M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $11.58B | 1,544.78% |
US
|
|
| $32.89B | 4,572.03% |
FR
|
|
| $6.22B | 784.09% |
JP
|
|
| $20.84B | 2,860.41% |
US
|
|
| $10.77B | 1,430.66% |
CH
|
